The United States Department Of Naval Medical Research Command (NMRC) intends to award a sole source contract, CareDX Lab Solutions., West Chester, PA. 19382. This notice is not a request for competitive proposals however If interested Government shall consider all responses.

The mission of the DoD Bone Marrow Program is to provide treatment for Armed Forces personnel after exposure to radiation and chemical weapons and to conduct research to improve management of radiation injuries. When prescribed 90% of drugs work only in 30-50% this is because 90% of individuals are likely to have different clinically actionable pharmacogenetic genotype.
There is a strong and well documented correlation between drug efficacy and variation in genes responsible for drug metabolism or transport (Pharmacogenetics; PGx).

Design and development of NGS-based assay for detection of pharmacogenetic variants involved in modulating response to Tacrolimus, Cyclophosphamide, Mycophenolate mofetil and Methotrexate, with feasibility studies completed by end of FY24. The assay utilizes hybrid capture technology, which provides better performance across various sample types and lower dropout rates, compared to other enrichment methods, e.g., PCR-based. The assay will be complemented by companion software for data interpretation. Period Of Performance Sep 6 2023 - Feb 5 2024/ QTY/-5mos. See attached J&A for Specifics.

Email your Quote to the following:

max.grogl1.civ@health.mil

deborah.m.sharpe2.civ@health.mil

shamai.m.carter.civ@health.mil

Attachments/Links